The Latest Breaking News from DXCM

DexCom is gearing up to announce its second-quarter results this month, and analysts are anticipating a double-digit increase in the company’s bottom-line figure.

Despite DexCom’s underperformance compared to its industry, Wall Street analysts remain optimistic about the stock’s prospects.

The healthcare industry is poised for tremendous growth driven by the aging population and rising incidence of chronic diseases. Hence, quality healthcare stocks, Danaher (DHR), Amgen (AMGN), and DexCom (DXCM), benefiting from an aging population, might be worth looking into. Read more….

S&P 500 stocks DexCom, Blackstone and Royal Caribbean lead five stocks around buy points after Fed chief Jerome Powell helped buoy markets.

These S&P 500 stocks are industry leaders with good fundamentals and bullish charts. They may be right for your portfolio or your watchlist.

Dexcom topped third-quarter expectations, shrugging off concerns new weight-loss drugs would undercut its sales. DXCM stock popped Friday.

The Dow ended a 13-day streak as the Nasdaq led an ugly reversal. Tesla has a new buy point while Intel and Roku jumped late.

Dexcom reported June-quarter earnings and revenue that topped Wall Street analyst targets and raised its full-year sales outlook.

Several stocks are near buy points, amid an orderly market pullback as Apple and other giants hold strong.

The market rally saw modest losses Monday as Apple dipped after unveiling its $3,499 Vision Pro goggles. Tesla leads five stocks in buy areas.

The EV giant broke out this week, leading a group of stocks around buy points as the market rally attempts to gather steam.